StreetInsider.com News Articles

Form 144 Pharvaris N.V. Filed by: Lu Peng

Thu, 18 Jun 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260618/26666494.html

Form 144 Pharvaris N.V. Filed by: Lu Peng

Thu, 18 Jun 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260618/26666494.html

Form 4 Pharvaris N.V. For: Jun 17 Filed by: Modig Berndt

Wed, 17 Jun 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20260617/26661122.html

Form 4 Pharvaris N.V. For: Jun 17 Filed by: Modig Berndt

Wed, 17 Jun 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20260617/26661122.html

Form 4 Pharvaris N.V. For: Jun 12 Filed by: Lu Peng

Tue, 16 Jun 2026 17:50:00 -0400

si-local-file:///var/storage/secattach/20260616/26655459.html

Form 4 Pharvaris N.V. For: Jun 12 Filed by: Lu Peng

Tue, 16 Jun 2026 17:50:00 -0400

si-local-file:///var/storage/secattach/20260616/26655459.html

H.C. Wainwright Reiterates Buy Rating on Pharvaris B.V. (PHVS)

Tue, 16 Jun 2026 06:44:57 -0400

H.C. Wainwright analyst Patrick R. Trucchio reiterated a Buy rating and $60.00 price target on Pharvaris B.V. (NASDAQ: PHVS).

The analyst commented: "European Academy of Allergy and Clinical Immunology (EAACI) 2026 reinforced deucrictibant's dual-use hereditary angioedema (HAE) profile across treatment settings. Pharvaris presented eight abstracts at the EAACI 2026 Congress (June 12–15, Istanbul). Most consequential, in our view, was the integrated cardiovascular/QT safety analysis (~570 participants), which showed a clean profile and addresses a key mechanistic concern for a systemically active bradykinin B2 receptor antagonist. The qualitative Phase 3 RAPIDe-3 patient voices study found that 45.7% of patients judged deucrictibant-treated attacks

Form 4 Pharvaris N.V. For: Jun 11 Filed by: Lu Peng

Mon, 15 Jun 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260615/26648667.html

Form 4 Pharvaris N.V. For: Jun 11 Filed by: Lu Peng

Mon, 15 Jun 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260615/26648667.html

Form 144 Pharvaris N.V. Filed by: Modig Berndt

Mon, 15 Jun 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260615/26648245.html

Form 144 Pharvaris N.V. Filed by: Modig Berndt

Mon, 15 Jun 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260615/26648245.html

Pharvaris presents data on deucrictibant for hereditary angioedema treatment

Mon, 15 Jun 2026 06:50:46 -0400

Pharvaris (NASDAQ: PHVS) presented clinical data on deucrictibant at the European Academy of Allergy and Clinical Immunology Annual Congress held June 12-15, 2026, in Istanbul, Turkey.

The company reported results from the RAPIDe-3 Phase 3 study evaluating deucrictibant immediate-release capsule (20 mg) for on-demand treatment of hereditary angioedema (HAE) attacks in participants 12 years and older. The study showed a median time to onset of symptom relief of 1.28 hours with deucrictibant versus over 12 hours with placebo. Complete resolution of attack symptoms occurred at a median of 11.95 hours with deucrictibant compared to over 48 hours with placebo.

In the study,

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

Mon, 15 Jun 2026 06:50:00 -0400

Results from prespecified assessment of End of Progression™ in the RAPIDe-3 Phase 3 study and clinical relevance of this newly-defined endpoint detailed in an oral presentation
Evidence on the cardiovascular safety profile of deucrictibant in clinical studies to date presented

ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations from the European Academy

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

Mon, 15 Jun 2026 06:50:00 -0400

Results from prespecified assessment of End of Progression™ in the RAPIDe-3 Phase 3 study and clinical relevance of this newly-defined endpoint detailed in an oral presentation
Evidence on the cardiovascular safety profile of deucrictibant in clinical studies to date presented

Form 6-K Pharvaris N.V. For: Jun 11

Thu, 11 Jun 2026 06:52:00 -0400

si-local-file:///var/storage/secattach/20260611/26632348.html

Form 6-K Pharvaris N.V. For: Jun 11

Thu, 11 Jun 2026 06:52:00 -0400

si-local-file:///var/storage/secattach/20260611/26632348.html

Pharvaris Announces Annual General Meeting of Shareholders

Thu, 11 Jun 2026 06:50:00 -0400

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).

All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are

Pharvaris Announces Annual General Meeting of Shareholders

Thu, 11 Jun 2026 06:50:00 -0400

All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are

Form 4 Pharvaris N.V. For: Jun 04 Filed by: Nijdam Anna

Mon, 08 Jun 2026 14:54:00 -0400

si-local-file:///var/storage/secattach/20260608/26616811.html

Form 4 Pharvaris N.V. For: Jun 04 Filed by: Nijdam Anna

Mon, 08 Jun 2026 14:54:00 -0400

si-local-file:///var/storage/secattach/20260608/26616811.html

Form 144 Pharvaris N.V. Filed by: Nijdam Anna

Thu, 04 Jun 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260604/26607147.html

Form 144 Pharvaris N.V. Filed by: Nijdam Anna

Thu, 04 Jun 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260604/26607147.html

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

Fri, 29 May 2026 06:50:00 -0400

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, to be held from June 12-15, 2026, in Istanbul, Turkey.

Details of

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

Fri, 29 May 2026 06:50:00 -0400

Details of

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

Fri, 29 May 2026 06:50:00 -0400

Details of